Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Hemogenyx Pharma Plc (LON:HEMO) Single CBR Can Treat Multiple Viruses
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Hemogenyx Pharma Plc Update With The Appointment of Medical Director
One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
Hemogenyx Pharma Plc (AIM:HEMO) CBR Update
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Hemogenyx Pharma Plc (AIM: HEMO) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Hemogenyx Pharma Plc (HEMO.L) Hemo-CAR-T partnership with WuXi ATU
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharma Plc (HEMO.L) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Hemogenyx Pharma Plc (HEMO.L) Lease of New York Mink Building Custom Laboratory
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharma Plc (HEMO.L) CDX Licence Agreement
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
Hemogenyx Pharma Plc (HEMO.L) U.S. Approval and Issuance of CDX Antibody Patent
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.
Hemogenyx Pharma Plc (HEMO.L) Termination of Mint Facility; Admission of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces that, pursuant to the redemption, sale and conversion of convertible unsecured loan